Table 1.
Normal endothelial function | Endothelial dysfunction | Mechanisms |
---|---|---|
Normal NO bioavailability and vasodilation | ↓NO bioavailability and vasodilation | ↓eNOS, eNOS uncoupling, ↑NO breakdown (ROS) |
↑Prostacyclin | ↓Prostacyclin | ↓Prostacyclin synthase |
↑EDHF-mediated responses | ↓EDHF-mediated responses | |
Normal vasoconstrictor levels | ↑Vasoconstriction | ↑ET-1, PGH2 and other endothelium-derived factors |
Anti-inflammatory properties | Pro-inflammatory properties | ↑Adhesion molecules, ↑cytokines |
↓Endothelial permeability | ↑Endothelial permeability | |
Anti-thrombotic properties | Pro-thrombotic properties | ↑PAI-1, vWF, P-selectin, ↑platelet activity |
Normal fibrinolytic activity | ↓Fibrinolytic activity | |
↓Oxidative stress | ↑Oxidative stress | ↑NADPH oxidase, eNOS uncoupling, other enzymes, ↓antioxidant defense |
Anti-atherogenic properties | Pro-atherogenic properties | ↑FFA, ↑LDL oxidation, ↑AGE + above described mechanisms |
Normal quantity and quality of EPC | ↓Quantity and quality of EPC | Weak bone marrow mobilization, ↓proliferation, ↓survival, ↑ROS |
Normal vascular structure and angiogenesis | Remodelling | Changes in growth factors, inflammation, matrix proteins, etc. |
EDHF: endothelium-derived hyperpolarizing factor; ROS: reactive oxygen species; PAI-1: plasminogen activator inhibitor-1; vWF: von Willebrand factor; eNOS: endothelial nitric oxide synthase; PGH2: prostaglandin H2; EPC: endothelial progenitor cells; NADPH: nicotinamide adenine dinucleotide phosphate; AGE: advanced glycation end products; LDL: low-density lipoprotein; FFA: free fatty acids.